Menu
← Oncology Approval Tracker
FDA DECISION ·
Xalkori oral pellets
crizotinib · Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
An oral pellet presentation for approved ALK- or ROS1-positive metastatic NSCLC in adults, ALK-positive relapsed or refractory systemic anaplastic large cell lymphoma in children aged one year or older and young adults, and unresectable, recurrent or refractory ALK-positive inflammatory myofibroblastic tumor in adults and children aged one year or older.
LAMPGEN ANALYSIS
Why it matters
The formulation provides an alternative to swallowing intact crizotinib capsules.
What research teams should watch
Train patients and caregivers on opening the pellet shell and preparing the full dose according to the formulation's label.
PRIMARY RECORDS